LONDON, Sept 7 (Reuters) - Roche Holding AG believes it has moved into pole position in the race to develop an Alzheimer's drug that can change the course of the disease after its rivals suffered setbacks in the past month.
The Swiss drugmaker has more than doubled the size of a clinical trial of its experimental drug gantenerumab in patients who have yet to develop dementia, putting it in the vanguard of attempts to catch the disease in its early stages.
"The playing field has changed dramatically and gantenerumab is now the most advanced monoclonal antibody in early Alzheimer's and the next big news to read out in this space," Luca Santarelli, Roche's head of neuroscience, said in an interview.
A successful Alzheimer's treatment could reap multiple billions of dollars in annual sales. However, many experts believe that treatment would have to be delivered before patients show signs of dementia because brain damage may be irreversible after that point.
"We targeted this space four years ago and our trial started at the end of 2010, so we are way ahead," Santarelli said.
Results from the study in early, or prodromal, Alzheimer's patients who do not yet have dementia are expected in 2015. The decision to increase the number of patients to 770 from 360 has made it a pivotal, or final-stage Phase III, trial.
While the project is high-risk and the approach unproven, Roche is hopeful that it will see an effect because previous brain scan tests have shown that gantenerumab can reduce amyloid plaques in the brain, which are linked to Alzheimer's, more rapidly than other drugs.
If the results are very strong, Roche may be able to file for marketing approval based on a single trial, given the high medical need, though regulators normally require further tests.
Roche has three other drugs in clinical tests, including crenezumab, which has been chosen for a U.S. government-backed trial in a group of Colombians with a genetic mutation that leads to Alzheimer's in their forties.
The failure of rival antibody drugs bapineuzumab, from Pfizer Inc, Johnson & Johnson and Elan Corp , and solanezumab, from Eli Lilly and Co, has dashed hopes for an immediate breakthrough against Alzheimer's. {ID:nL2E8JO5SY]
Both drugs were tested in patients who already had dementia.
Details of the unsuccessful trials with bapineuzumab will be presented at a medical conference in Stockholm on Tuesday, while results with solanezumab - which showed interesting but inconclusive signs of improvement in patients with mild disease - will be set out at a meeting in Boston on Oct. 8.
The tentative signs of an effect with solanezumab has prompted some industry analysts to suggest that it could be an option for patients with mild Alzheimer's or in the early stages of the disease. However, this would almost certainly require further trials, which would take about three years.
Santarelli said that a key strength of his team's approach with gantenerumab, which is partnered with Morphosys AG , was the decision to set rigorous selection criteria for patients, including diagnostic testing of spinal fluid.
The Roche study uses both cognitive testing and sampling of spinal fluid to ensure that all patients in the trial truly have pre-symptomatic Alzheimer's and not some other memory problem.
The decision to link treatment to a diagnostic test follows the highly successful pattern adopted by Roche in cancer medicine, where it is the world leader in terms of sales.
That makes it a somewhat onerous process for patients, who have to undergo a lumbar puncture, though Santarelli said that this had not discouraged patients who are aged 50 to 85 and have memory problems.
"I had some scepticism, but it turns out the mandatory lumbar puncture is not a major hurdle in recruiting patients," he said. (Editing by David Goodman)
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.